This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.
- Brand Names
- Solu-medrol
- Generic Name
- Methylprednisolone hemisuccinate
- DrugBank Accession Number
- DB14644
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Methylprednisolone hemisuccinate (DB14644)
- Weight
- Average: 474.55
Monoisotopic: 474.225368055 - Chemical Formula
- C26H34O8
- Synonyms
- Methylprednisolone hemisuccinate
- Methylprednisolone hydrogen succinate
- Methylprednisolone succinate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Acute gouty arthritis •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Ankylosing spondylitis (as) •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Berylliosis •••••••••••• •••••••••• ••••••• ••• •••••••• Management of Congenital adrenal hyperplasia (cah) •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Congenital hypoplastic anemia •••••••••••• •••••••••• ••••••• ••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Methylprednisolone sodium succinate (the sodium salt of methylprednisolone hemisuccinate) has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity.
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acarbose. Aceclofenac The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Acemetacin. Acenocoumarol Methylprednisolone hemisuccinate may increase the anticoagulant activities of Acenocoumarol. Acetohexamide The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acetohexamide. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Methylprednisolone sodium succinate LEC9GKY20K 2375-03-3 FQISKWAFAHGMGT-SGJOWKDISA-M - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Methylprednisolone Sodium Succinate for Injection Powder, for solution 1 g / vial Intramuscular; Intravenous Teva Italia S.R.L. 2000-03-01 Not applicable Canada 
Methylprednisolone Sodium Succinate for Injection Powder, for solution 5 g / vial Intramuscular; Intravenous Teva Italia S.R.L. Not applicable Not applicable Canada Methylprednisolone Sodium Succinate for Injection Powder, for solution 500 mg / vial Intramuscular; Intravenous Teva Italia S.R.L. 2000-03-01 Not applicable Canada Methylprednisolone Sodium Succinate for Injection Powder, for solution 125 mg / vial Intramuscular; Intravenous Teva Italia S.R.L. 2000-03-01 Not applicable Canada Methylprednisolone Sodium Succinate for Injection Powder, for solution 40 mg / vial Intramuscular; Intravenous Teva Italia S.R.L. 2000-03-01 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image A-methapred Injection, powder, for solution 125 mg/2mL Intramuscular; Intravenous Hospira, Inc. 2009-06-22 2013-05-01 US 
A-methapred Injection, powder, lyophilized, for solution 125 mg/2mL Intramuscular; Intravenous Hospira, Inc. 2006-10-06 2010-07-01 US A-methapred Injection, powder, for solution 40 mg/1mL Intramuscular; Intravenous Hospira, Inc. 2009-07-14 2013-05-01 US A-methapred Injection, powder, lyophilized, for solution 40 mg/1mL Intramuscular; Intravenous Hospira, Inc. 2006-10-06 2010-07-01 US Methylprednisolone Sodium Succinate Injection, powder, lyophilized, for solution 125 mg/2mL Intramuscular; Intravenous GeneYork Pharmaceuticals Group LLC 2021-04-20 Not applicable US
Categories
- Drug Categories
- Adrenal Cortex Hormones
- Adrenals
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Central Nervous System Agents
- Compounds used in a research, industrial, or household setting
- Corticosteroids
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A5 Inducers
- Cytochrome P-450 CYP3A5 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Fused-Ring Compounds
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Neuroprotective Agents
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Protective Agents
- Steroids
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5GMR90S4KN
- CAS number
- 2921-57-5
- InChI Key
- IMBXEJJVJRTNOW-XYMSELFBSA-N
- InChI
- InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
- IUPAC Name
- 4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
- SMILES
- [H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
References
- General References
- FDA Approved Drug Products: Solu-Medrol (methylprednisolone sodium succinate) for injection [Link]
- External Links
- ChemSpider
- 16034
- ChEBI
- 135765
- ChEMBL
- CHEMBL1201265
- ZINC
- ZINC000003977781
- Wikipedia
- Methylprednisolone
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Kidney Transplant Patients 1 somestatus stop reason just information to hide Not Available Completed Other Administration, Intravenous / Healthy Volunteers (HV) / Intranasal Administration / Methylprednisone Administration 1 somestatus stop reason just information to hide Not Available Completed Prevention Systemic Inflammatory Response Syndrome (SIRS) / Valvular Heart Diseases 1 somestatus stop reason just information to hide Not Available Completed Treatment Abdominal Aortic Aneurysm (AAA) 1 somestatus stop reason just information to hide Not Available Completed Treatment Aortic Stenosis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intramuscular; Intravenous 125 mg/2mL Solution Intravenous 165.740 mg Injection, powder, lyophilized, for solution Intravenous 500 mg Injection, solution Intramuscular; Intravenous 250 mg Solution Parenteral 165.74 mg Injection Intramuscular; Intravenous Injection, solution Intramuscular; Intravenous 1000 mg Injection, powder, for solution Parenteral 16 mg Injection, powder, for solution Parenteral 32 mg Injection Intramuscular; Intravenous 1 g/16mL Injection Intramuscular; Intravenous 125 mg/2mL Injection Intramuscular; Intravenous 40 mg/1mL Injection Intramuscular; Intravenous 500 mg/8mL Injection, powder, for solution 171 mg/2ml Injection, powder, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, for solution Intramuscular; Intravenous 125 mg Injection, powder, for solution Intramuscular; Intravenous 125 mg/1 Injection, powder, for solution Intramuscular; Intravenous 40 mg/1 Injection, powder, for solution Intramuscular; Intravenous 500 mg/1 Injection, powder, for solution Intramuscular; Intravenous 500 mg Injection, powder, for solution; injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg Injection, powder, lyophilized, for solution 684 mg Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/16mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/8mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/2mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 2 g/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 2 g/30.6mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg/1mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/4mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/8mL Powder, for solution Intramuscular; Intravenous 1 g / vial Powder, for solution Intramuscular; Intravenous 125 mg / vial Powder, for solution Intramuscular; Intravenous 40 mg / vial Powder, for solution Intramuscular; Intravenous 5 g / vial Powder, for solution Intramuscular; Intravenous 500 mg / vial Injection, powder, lyophilized, for solution Intramuscular; Intravenous 20 mg Injection, powder, lyophilized, for solution Intramuscular; Intravenous 250 mg Injection Intramuscular; Intravenous 250 mg Injection Intramuscular; Intravenous 40 mg Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg Injection, solution Intramuscular; Intravenous 125 mg Injection, solution Intramuscular; Intravenous 15.78 mg Injection, powder, for solution 125 mg Injection Intramuscular; Intravenous 20 mg Injection, powder, for solution Tablet Solution 500.000 mg Injection, powder, for solution Parenteral 1000 mg Powder Intramuscular; Intravenous 1000 mg/1vial Injection, powder, for solution Parenteral 500 mg Injection, powder, for solution 125 mg/2ml Injection, powder, for solution 500 mg Injection, powder, for solution Intramuscular; Intravenous 1000 MG/16ML Injection, powder, for solution Intramuscular; Intravenous 2000 MG/32ML Injection, powder, for solution Intramuscular; Intravenous 40 MG/ML Injection, powder, for solution Intracavernous; Intramuscular 40 mg/1 Injection, powder, for solution Intramuscular; Intravenous 1 g/1mL Injection, powder, for solution Intramuscular; Intravenous 1 g/8mL Injection, powder, for solution Intramuscular; Intravenous 125 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 2 g/30.6mL Injection, powder, for solution Intramuscular; Intravenous 40 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/4mL Injection, powder, for solution Intravenous 1 g/1 Injection, powder, for solution; kit Intramuscular; Intravenous 2 g/30.6mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/1mL Kit; powder Intramuscular; Intravenous 1 g / vial Kit; powder Intramuscular; Intravenous 125 mg / vial Kit; powder Intramuscular; Intravenous 40 mg / vial Kit; powder Intramuscular; Intravenous 500 mg / vial Kit; powder, for solution Intramuscular; Intravenous 1 g / vial Kit; powder, for solution Intramuscular; Intravenous 125 mg / vial Kit; powder, for solution Intramuscular; Intravenous 40 mg / vial Kit; powder, for solution Intramuscular; Intravenous 500 mg / vial Powder, for solution Intravenous 125 mg/1mL Powder Intramuscular; Intravenous 125 mg/1vial Powder Intramuscular; Intravenous 40 mg/1vial Powder Intramuscular; Intravenous 500 mg/1vial Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg Injection, powder, for solution Intramuscular; Intravenous 500 mg/8ml Powder Intramuscular; Intravenous 1000 MG Powder Intramuscular; Intravenous 500 MG Powder, for solution Intramuscular; Intravenous; Rectal 125 mg / vial Powder, for solution Intramuscular; Intravenous; Rectal 40 mg / vial Injection, powder, for solution Intramuscular; Intravenous 20 mg Injection, powder, for solution Intramuscular; Intravenous 250 mg Injection, powder, for solution Intramuscular; Intravenous 40 mg Injection, powder, for solution Intramuscular; Intravenous Injection Parenteral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0264 mg/mL ALOGPS logP 2.43 ALOGPS logP 1.83 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 3.66 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 138.2 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 123.09 m3·mol-1 Chemaxon Polarizability 49.87 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-052r-0004900000-c2cd56187e228f386ceb Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-052f-0009200000-755bd4b2c1e0d8817b2e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-052r-4338900000-db8155cb7658af04a306 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0076-2009000000-a83c708fc156222b0abb Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0571-4689300000-bbdbeaec99edf0f90ce5 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00fr-8009100000-519aed3487b0275075d8 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 226.0317817 predictedDarkChem Lite v0.1.0 [M+H]+ 222.3177817 predictedDarkChem Lite v0.1.0 [M+Na]+ 223.0501817 predictedDarkChem Lite v0.1.0
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)
- Specific Function
- 1,8-cineole 2-exo-monooxygenase activity
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228)
- Specific Function
- aromatase activity
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
Drug created at September 01, 2018 21:25 / Updated at October 30, 2024 23:03